This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: percutaneous coronary intervention

November 2023 Br J Cardiol 2023;30:158–60 doi:10.5837/bjc.2023.045

Brachial artery approach for managing retroperitoneal bleed following coronary intervention for STEMI

Muhammad Usman Shah, Krishna Poudyal, Ramy Goubran, Adnan Ahmed, Syed Yaseen Naqvi

Abstract

Background Radial artery is the preferred route of access for percutaneous coronary intervention (PCI) as the femoral artery is associated with a greater incidence of bleeding complications.1–5 Often such complications require open surgical repair.4,6 However, percutaneous treatment with covered stents may represent an alternate option. Case presentation A man in his 50s, fit and well and on no routine medications, developed chest pain and posterior ST-elevation myocardial infarction (STEMI) with 2 mm ST-elevation in posterior leads V7, 8 and 9, and 2 mm ST-depression in leads V2 and 3, complicated by cardiogenic shock and out-of-hospital c

| Full text

June 2020 Br J Cardiol 2020;27:51–54 doi:10.5837/bjc.2020.017

Impact of COVID-19 on primary percutaneous coronary intervention centres in the UK: a survey

Ahmed M Adlan, Ven G Lim, Gurpreet Dhillon, Hibba Kurdi, Gemina Doolub, Nadir Elamin, Amir Aziz, Sanjay Sastry, Gershan Davis

Abstract

Introduction Coronavirus disease-2019 (COVID-19) was declared a pandemic by the World Health Organization on 12th March 2020.1 Subsequently, on 20th March 2020, the National Health Service (NHS) England in collaboration with the British Cardiovascular Society (BCS), the British Cardiovascular Interventional Society (BCIS) and the British Heart Rhythm Society (BHRS) published guidelines for the management of cardiology patients during the coronavirus pandemic.2 Briefly, the guidelines recommended that: all non-urgent elective inpatient/day case procedures should be postponed primary percutaneous coronary intervention (PCI) should continue to b

| Full text

July 2019 Br J Cardiol 2019;26:110–3 doi:10.5837/bjc.2019.024

A simple technique for IMA graft angiography and PCI using contralateral radial access

Matthew E Li Kam Wa, Pitt O Lim

Abstract

Introduction While many in the interventional cardiology community consider the debate of routine radial versus femoral access for coronary angiography to be all but over,1-5 there, nonetheless, continues to be a wide variation in the uptake of transradial access worldwide.6,7 Even putting the preferences of transradial enthusiasts aside, it also seems that patients who have had experience of both access routes prefer use of the radial artery.8 Nonetheless, femoral access undoubtedly continues to remain relevant in situations such as large bore and complex intervention, the need for mechanical support devices, and structural intervention. One

| Full text
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI

August 2018 Br J Cardiol 2018;25(suppl 1):S6–S11 doi:10.5837/bjc.2018.s02

Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI

Tarek Nafee, Gerald Chi, Fahad AlKhalfan, Serge Korjian, Yazan Daaboul, Seyedmahdi Pahlavani, Usama Talib, Aravind Reddy Kuchkuntla, Mahshid Mir, Mathieu Kerneis, C Michael Gibson

Abstract

Background, epidemiology and rationale for study The PIONEER AF-PCI (Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention) trial addressed an important medical question, which is potentially relevant for the 20–45% of atrial fibrillation (AF) patients who also have coronary artery disease and are likely to undergo percutaneous coronary intervention (PCI). Prior to the PIONEER AF-PCI trial, there was an unmet need for evidence-based recommendati

| Full text

November 2017 Br J Cardiol 2017;24:129

REDUCE shows non-inferiority of short versus long DAPT in acute coronary syndrome

BJC Staff

Abstract

The COMBO™ dual therapy stent REDUCE (Short-term Dual Anti Platelet Therapy in Patients with ACS Treated with the COMBO Dual-therapy Stent), a physician-initiated, prospective, multi-centre, randomised study, was conducted in 36 hospitals in Europe and Asia, enrolling a total of 1,496 ACS patients. The study was designed to demonstrate non-inferiority of a strategy of short-term (three months) dual antiplatelet therapy (DAPT) compared to standard 12-month DAPT in patients with ACS treated with a dual-therapy stent. The stent used in the study COMBO™ (OrbusNeich) is a sirolimus-eluting stent with an abluminal biodegradable polymer matrix,

| Full text

October 2017

ESC 2017: RE-DUAL PCI shows benefits for dabigatran

BJC staff

Abstract

Approximately 20–30% of patients with AF, who are continuously taking an oral anticoagulant to reduce their risk of AF-related stroke, have coexisting coronary artery disease and may require PCI. The current practice of administering triple therapy with warfarin and two antiplatelet agents in patients with AF after a PCI is associated with high rates of major bleeding. RE-DUAL PCI tested an alternative treatment strategy: dual therapy with dabigatran and a single antiplatelet agent (P2Y12 inhibitor). Selected for one of the meeting’s hotline sessions and simultaneously published in the New England Journal of Medicine (https://doi.org/10.

| Full text
Risk factors for femoral arterial complications and management

November 2016 Br J Cardiol 2016;23:155–8 doi:10.5837/bjc.2016.040

Risk factors for femoral arterial complications and management

Shabnam Rashid, Stephanie Hughes

Abstract

(more…)

| Full text
When you can’t obtain a history…

April 2016 Br J Cardiol 2016;23:78 doi:10.5837/bjc.2016.017 Online First

When you can’t obtain a history…

Luciano Candilio, Juliana Duku, Alexander W Y Chen

Abstract

Figure 1. Patient chest X-ray showing a ‘full metal jacket’ Her physical examination and vital signs were unremarkable. Routine blood tests had been requested. Resting 12-lead electrocardiogram (ECG) showed left bundle branch block; no previous ECGs were available for comparison. A chest X-ray was performed, which gave another clue to the diagnosis… The chest radiograph (figure 1) shows clear lung fields, normal cardiac contour and, more importantly, a radio-opaque structure across the anterior surface of her heart. This is sometimes termed a ‘full metal jacket’, implying extensive stenting of a coronary artery in its entirety f

| Full text

February 2015 Br J Cardiol 2015;22:27–30 doi:10.5837/bjc.2015.003 Online First

Incidence of cardiac surgery following PCI: insights from a high-volume, non-surgical, UK centre

Andrew Whittaker, Peregrine Green, Giles Coverdale, Omar Rana, Terry Levy

Abstract

Introduction It is accepted that coronary revascularisation with coronary artery bypass graft surgery (CABG) provides both symptomatic and prognostic benefit in patients with multi-vessel coronary artery disease (mvCAD).1,2 Both percutaneous coronary intervention (PCI) and CABG provide better relief of angina symptoms than medical therapy alone.1,3 Large, randomised-controlled trials (RCTs), in recent years, have demonstrated that CABG offers an improved outcome in patients with complex three-vessel coronary artery disease (CAD), especially in those with co-existing diabetes mellitus.4,5 However, in patients with one- or two-vessel CAD, PCI o

| Full text

September 2014 Br J Cardiol 2014;21:98

New NICE guidance published

BJCardio Staff

Abstract

The National Institute for Health and Care Excellence (NICE) has said that thousands of people with atrial fibrillation (AF) could be prevented from having strokes, disability or death if its new guidance is followed. It says many patients with AF are not being appropriately anticoagulated and highlights how there has not been widespread uptake of novel oral anticoagulant drugs (NOACs) which were approved by NICE in 2012. Clinical guideline 180 published in June 2014 updates and replaces the 2006 NICE clinical guideline 36. The full guidance can be found at http://www.nice.org.uk/guidance/CG180 NICE Chair, Professor David Haslam writes on the

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now